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PURPOSE AND SCOPE OF THE GUIDELINE
The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis. Biologic therapies have now been in use for over 10 years, and with accrued patient-years exposure and clinical experience, many areas that were covered in previous versions of the guideline are now part of the Summary of Product Characteristics (SPC) and/or routine care so that specific recommendations are redundant (see Toolkit A: Summary of licensed indications and posology for biologic therapy, in Supporting information 2). Therefore, in this update we focus on areas where there has been a major change in the evidence base or clinical practice, where practice is very varied and/or where clear consensus or guidelines are lacking (see section 3.1 in Supporting information 1).
This set of guidelines has been developed using the BAD's recommended methodology 1 with reference to the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument [www.agreetrust.org] 2 and the Grading of Recommendations Assessment, Development and Evaluation (GRADE). 3 Recommendations were developed for implementation in the NHS (U.K.). Note that the guideline recommendations will normally fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline assumes that prescribers cross-reference a drug's SPC to inform clinical decision-making for individual patients. Where relevant, this guidance applies to biosimilars (similar biological medical products), subject to recommendations given within the BAD position statement 4 and EMA guidelines. 5 This guidance does not cover agents licensed outside the UK or use of biologic therapies for indications other than psoriasis or use when psoriatic arthritis is the main indication.
To aid implementation, this executive summary contains only key clinical findings and recommendations (see Table 2 ) derived from systematic review of the evidence. The strength of recommendation is expressed by the wording and symbols featured in Table 1 . Good practice point (GPP) recommendations are derived from informal consensus. A decision aid, informed by the evidence reviews, has been developed to help patients and clinicians choose the appropriate biologic therapy (see Table 3 ) and a suggested schedule for screening and monitoring (see Table 4 ) is also provided. The full version of the guideline is available online (Supporting information 1) and includes details on methodology, six systematic reviews with appraisal and discussion of the clinical evidence.
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Strength Wording Symbols Definition
Strong recommendation for the use of an intervention "Offer" (or similar, e.g.
"Provide", "Advise", "Screen", etc.)  Benefits of the intervention outweigh the risks; most patients would choose the intervention whilst only a small proportion would not; for clinicians, most of their patients would receive the intervention; for policy makers, it would be a useful performance indicator.
Weak recommendation for the use of an intervention "Consider"  Risks and benefits of the intervention are finely balanced; many patients would choose the intervention but many would not; clinicians would need to consider the pros and cons for the patient in the context of the evidence; for policy makers, it would be a poor performance indicator where variability in practice is expected.
No recommendation Θ Insufficient evidence to support any recommendation.
Strong recommendation against the use of an intervention "Do not offer"  Risks of the intervention outweigh the benefits; most patients would not choose the intervention whilst only a small proportion would; for clinicians, most of their patients would not receive the intervention.  the psoriasis is severe at localised sites and associated with significant functional impairment and/or high levels of distress (for example nail disease or involvement of high-impact and difficult-to-treat sites such as the face, scalp, palms, soles, flexures and genitals) R5 Consider biologic therapy earlier in the treatment pathway (for example, if methotrexate has failed, is not tolerated or is contra-indicated) in people with psoriasis that fulfils the disease severity criteria and who also have active psoriatic arthritis IV or who have psoriasis that is persistent (i.e. that relapses rapidly off a therapy that cannot be continued long-term V )  Prescribing biologic therapy R6 Be aware of the benefits of, contraindications to and adverse effects associated with biologic therapies and reference the drug-specific SPCs VI  R7 Provide high-quality, evidence-based information to people being prescribed biologic therapies. Explain the risks and benefits to people undergoing this treatment (and their families or carers where appropriate), using absolute risks and natural frequencies when possible (see Table 3 : Decision aid). Allow them adequate time to consider the information.
 R8 Support and advice should be offered to people with psoriasis (and their families or carers where appropriate) by healthcare professionals who are trained and competent in the use of biologic therapies  Reviewing biologic therapy R9 Assess initial response to biologic therapy in people with psoriasis at time points appropriate for the drug in question, and then on a regular basis during therapy (for example, every 6 months)  R10 Review response to biologic therapy by taking into account:
 psoriasis disease severity compared with baseline (for example, Psoriasis Area and Severity Index [PASI] baseline to endpoint score VII )
 the agreed treatment goal  control of psoriatic arthritis disease activity and/or inflammatory bowel disease (in consultation with a rheumatologist and/or gastroenterologist)
 the impact of psoriasis on the person's physical, psychological and social functioning  the benefits versus the risks of continued treatment  the views of the person undergoing treatment (and their family or carers, where appropriate)  adherence to the treatment

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R11 Assess whether the minimal response criteria have been met, as defined by:
 a 50% or greater reduction in baseline disease severity (for example, PASI 50 response, or % BSA where the PASI is not applicable) and
 clinically relevant improvement in physical, psychological or social functioning (for example, a 4-point or greater improvement in DLQI or resolution of low mood)  R12 Consider changing to an alternative therapy, including another biologic therapy, if any of the following applies:
 the psoriasis does not achieve the minimum response criteria (primary failuresee R11)
 the psoriasis initially responds but subsequently loses this response (secondary failure)
 the current biologic therapy cannot be tolerated or becomes contraindicated  Choice of biologic therapy: general considerations R13 Take into account both psoriasis and psoriatic arthritis before initiating or making changes to biologic therapy, and:
 manage treatment in consultation with a rheumatologist or paediatric rheumatologist  be aware that the presence of and phenotype of psoriatic arthritis (for example, peripheral versus axial disease) may influence access to, choice and dose of, biologic therapy  R14 Tailor the choice of agent to the needs of the person and take into account the following factors (see Table 3 : Decision aid):
Psoriasis factors the goal of therapy (for example a PGA of clear or nearly clear) disease phenotype and pattern of activity disease severity and impact the presence of psoriatic arthritis (in consultation with an adult or paediatric rheumatologist) outcomes to previous treatments for psoriasis Other factors person's age past or current co-morbid conditions (for example, inflammatory bowel disease, cardiovascular disease) conception plans body weight the person's views and any stated preference on administration route or frequency adherence  R15 Be aware that the recommended first-line choice of biologic therapy will not be appropriate for every individual; use the decision aid and with reference to R14 to inform choice of alternative licensed biologic therapies.

Choice of biologic therapy in adults: first line R16
Offer ustekinumab as a first-line biologic agent to adults with psoriasis who fulfil the criteria for biologic therapy (see also R4 and R5) 
Accepted Article
VIII 'Very severe' relates to the physician's global assessment or/and the NICE definition ((PASI 20 or more and DLQI 18 or more) and failed to respond to standard systemic therapies such as ciclosporin, methotrexate or PUVA (psoralen and long-wave ultraviolet radiation), or the person is intolerant to or has a contraindication to these treatments.) IX Off-licence R17 Offer adalimumab as a first-line biologic agent to adults with psoriasis particularly when psoriatic arthropathy is a consideration  R18 Consider secukinumab as a first-line biologic agent in adults with psoriasis, with or without psoriatic arthritis 
Choice of biologic therapy in adults: second line R19
Offer any of the currently licensed biologic therapies when psoriasis has not responded to a first biologic therapy. Use the decision aid (Table 3) and take into account all factors detailed in R14 to select the most appropriate agent.

Consideration R20
Reserve infliximab for use in people with very severe disease VIII or where other available biologic agents have failed or cannot be used 
What to do when a second or subsequent biologic therapy fails in adults R21
When a person's psoriasis responds inadequately to a second or subsequent biologic agent seek advice from a clinician with expertise in biologic therapy and consider any of the following strategies:
 reiterate advice about modifiable factors contributing to poor response (for example, obesity and poor adherence)
 optimise adjunctive therapy (for example, switch from oral to sub-cutaneous methotrexate)
 switch to an alternative biologic agent  consider non-biologic therapy approaches (for example inpatient topical therapy, phototherapy or standard systemic therapy)  When to consider dose escalation R22 Consider escalating the dose of biologic therapy in adults, where this is feasible and funded (see table below) when an inadequate primary response may be due to insufficient drug dosing (for example, in people who are obese or whose psoriasis relapses during the treatment cycle). Take into account that this may be associated with an increased risk of infection, and, depending on the drug, off-licence. 
Biologic agent Suggested dose-escalation strategy
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X Major congenital malformations reported in 3.6-5.0% of women exposed to anti-TNF compared with 1.5-4.7% in control groups (odds ratios [OR] = 1.32-1.64) biologic agent seek advice from a clinician with expertise in biologic therapy and consider any of the following strategies:
 switch to an alternative biologic agent  consider non-biologic therapy approaches (for example inpatient topical therapy or standard systemic therapy) Transitioning to/between biologic therapies R25 When choosing the transitioning strategy from one drug therapy to another and whether a therapy washout (or no washout) should be used, take into consideration:
 the pharmacology of the drugs that are being started and stopped (see Toolkit A: Summary of licensed indications and posology for biologic therapy, in Supporting information 2)
 the person's clinical circumstances  the person's views on the risks and benefits of transitioning option(s)  R26 Consider the following strategies when transitioning from standard systemic to biologic therapy:
 in stable disease, aim to allow 1 month to elapse between the last dose of any current standard systemic immunosuppressant psoriasis therapy (except methotrexate) and the planned date of biologic initiation  start a biologic therapy with no drug washout period in people taking methotrexate, or in people on other therapies where this would lead to unstable disease  when standard, systemic immunosuppressant therapy cannot be stopped (for example, in people for whom a disease flare would be severe or hazardous), rationalise use of therapy and stop as soon as possible (for example, when a minimum response has been achieved)  R27 When transitioning to a new biologic therapy (from a previous biologic therapy) consider using a 1-month washout period, or the length of the treatment cycle (whichever is longer), between the last dose of the current biologic therapy and the planned date of biologic initiation  Conception and pregnancy R28 Provide information about the possible effects of biologic therapy during conception and pregnancy including:
 the importance of controlling severe or unstable psoriasis to maintain maternal health  that most pregnancies reported in women taking biologic therapy at conception and during pregnancy have successful outcomes  that evidence about the effect of biologic therapy on conception and pregnancy mostly relates to TNF antagonists in women with rheumatological and inflammatory bowel disease; this evidence indicates a potential risk associated X

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XI For example, http://www.medicinesinpregnancy.org/Medicine--pregnancy XII There are no known interactions between biologic therapies and contraceptive methods (see drug-specific SPCs) with exposure to TNF antagonists but is of low quality, and may relate to other factors (for example, other co-therapies or the underlying disease) that the risk of fetal abnormalities in women with psoriasis who conceive on biologic therapy has not been adequately studied and therefore cannot be quantified  that maternal IgG, and therefore biologic drugs currently licensed for psoriasis, are actively transferred to the developing fetus during the second and third trimester and that the impact of this on fetal and neonatal development and risk of infection has not been adequately studied  that live vaccines must be avoided in infants born to mothers taking biologic therapy beyond 16 weeks' gestation  relevant patient information resources XI R29 Advise women of child-bearing potential who are starting biologic therapy for psoriasis to use effective contraception XII and discuss conception plans with the consultant supervising their care (see R30)
 R30 Discuss the risks and benefits of continuing versus stopping biologic therapy with women who are of child-bearing potential or who become pregnant. Offer advice on a case-bycase basis by taking into account the woman's views and the:
 course of psoriasis disease and the fetal outcome during any prior pregnancies  risk of severe or unstable psoriasis if the biologic therapy were stopped  physical, psychological and social functioning if the biologic therapy were stopped  options for alternative, non-biologic treatment strategies  R31 Assess whether biologic therapy for psoriasis can be stopped in women who become pregnant. Ensure consultation and information-sharing across specialities including with an obstetrician who has expertise in caring for pregnant women with medical problems. Collect pregnancy outcome data for safety registries, for example BADBIR in the U.K. and Republic of Ireland. 

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This article is protected by copyright. All rights reserved. NOTES 1. Take into account psoriasis factors (the goal of therapy e.g. PGA clear/nearly clear; disease phenotype and pattern of activity; disease severity and impact; presence of psoriatic arthritis; outcomes of previous treatment for psoriasis) and other factors (age; past or current co-morbid conditions; conception plans; body weight). 2. Take into account both psoriasis and psoriatic arthritis before initiating or making changes to biologic therapy, and manage treatment in consultation with a rheumatologist; be aware that the presence of and phenotype of psoriatic arthritis (for example, peripheral versus axial disease) may influence access to, choice and dose of, biologic therapy. 3. Consider changing to an alternative biologic therapy if any of the following applies: the psoriasis does not achieve the minimum response criteria (primary failure -see R11) or the psoriasis initially responds but subsequently loses this response (secondary failure) 4. Consider escalating the dose of biologic therapy in adults (R22) when an inadequate primary response may be due to insufficient drug dosing (for example, in people who are obese or whose psoriasis relapses during the treatment cycle). Take into account that dose escalation may be associated with an increased risk of infection, and, depending on the drug, off-licence and not funded. Currently, a dose-escalation strategy is not applicable to secukinumab or ixekizumab. 5. This guidance applies to biosimilars, subject to recommendations given within the BAD position statement and EMA guidelines. 4, 5 ccepted Article This article is protected by copyright. All rights reserved.
DECISION AID
This table supports the decision-making process during the consultation for patients and clinicians before the initiation of biologic therapy. It is complementary to the existing patient information leaflets (PILs; www.bad.org.uk/leaflets). All biologic therapies for the treatment of psoriasis require bloods tests before and during treatment. If you have psoriatic arthritis, your doctor will take this into consideration. You or your carer will learn to give the injection after training.
Frequently Asked Questions
You or your carer will learn to give the injection after training.
You will need to go to hospital where the injection will be given by a healthcare professional.
You or your carer will learn to give the injection after training You or your carer will learn to give the injection after training.
You may choose to have the injection given to you by a nurse in your home. Alternatively, you or your carer may learn to give the injection after training.
Does not apply
How long has this treatment been around for? The risk to the baby is unknown. Your dermatologist will discuss this with you.
The risk to the baby is unknown. Your dermatologist will discuss this with you.
During pregnancy, psoriasis may get better, stay the same, or become worse 
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AUDIT STANDARDS, DATA ITEMS AND DATA COLLECTION METHODOLOGY Dermatology teams involved in prescribing biologic interventions should use audit as a tool to monitor their service against national guidelines of care. The aim should be to ensure that the service is high in quality, safe and cost-effective. See Toolkit C: Audit standards, data items and data collection methodology, in Supporting information 2, for further details.
STAKEHOLDER INVOLVEMENT AND PEER REVIEW
The full version of the guideline was made available to the BAD membership, British Society for Paediatric Dermatology, British Dermatological Nursing Group, Primary Care Dermatological Society, British Society for Paediatric and Adolescent Rheumatology, British Society of Rheumatology, Royal College of Obstetrics and Gynaecology, Psoriasis and Psoriatic Arthritis Alliance, Psoriasis Association and relevant pharmaceutical companies (see Appendix F, in Supporting information 1, for the full list of stakeholders), comments from whom were actively considered by the GDG. Following further review, the finalized version was peer-reviewed by the Clinical Standards Unit of the BAD, made up of the Therapy & Guidelines Subcommittee (T&G), prior to submission for publication.
LIMITATIONS OF THE GUIDELINE
This document has been prepared on behalf of the BAD and is based on the best data available when the document was prepared. It is recognized that under certain conditions it may be necessary to deviate from the guidelines and that the results of future studies may require some of the recommendations herein to be changed. Failure to adhere to these guidelines should not necessarily be considered negligent, nor should adherence to these recommendations constitute a defence against a claim of negligence. Limiting the review to English language references was a pragmatic decision but the authors recognize this may exclude some important information published in other languages.
PLANS FOR GUIDELINE REVISION
This 2017 guideline updates the previous version. 9 An annual literature review is planned for this fastmoving subject and the recommendations updated where necessary, in line with the BAD's recommended guideline development methodology. 1
SUPPORTING INFORMATION
The full version of this guideline is available in the online Supporting information 1 document, which includes tables linking evidence to recommendations (LETR), details of the network meta-analysis, summary of included studies, forest plots, GRADE evidence profiles, PRISMA flow diagrams, list of excluded studies and search strategies. Supporting information 2 contains toolkits to aid implementation.
